NCT07890168Recruiting
Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following Primary PCI in STEMI Patients
Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following Primary PCI in STEMI Patients; A Prospective Cohort Study
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
This study aims to evaluate the combined predictive value of immune-inflammatory and metabolic biomarkers for coronary no-reflow following primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI), with the goal of improving early risk stratification and clinical decision-making.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 18 Oct 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 May 2027
- Lead sponsor
- Sohag University
- Diseases
- Coronary artery disease
- NCT number
- NCT07890168
What you commit to
- Study type: Observational
- Planned participants: 400
- From 1 Sept 2026 to the primary completion date, 1 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous coronary artery bypass graft surgery (CABG).
- Current use of chronic corticosteroid or immunosuppressive therapy.
Other illness
- Active infection or sepsis.
- Chronic inflammatory or autoimmune diseases.
- Hematological disorders.
- Active malignancy.
- Severe liver disease.
- End-stage renal disease requires dialysis.
Who the study is looking for
- Age ≥18 years old.
- Both sexes.
- Diagnosis of ST-segment elevation myocardial infarction (STEMI) according to current ESC/ACC guidelines.
- Presentation within 12 hours of symptom onset.
- Undergoing primary percutaneous coronary intervention (PCI) as the reperfusion strategy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sohag University Coordinator of this site? Confirm its status | Sohag | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.